Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.
Myeloma Center

Bibliography

Found 9 results
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is N  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
N
Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S, Sparano JA.  2011.  Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.. Cancer. 117(2):336-42.
Niesvizky R.  2013.  Immunomodulatory agents changing the landscape of multiple myeloma treatment.. Crit Rev Oncol Hematol. 88 Suppl 1:S1-4.
Niesvizky R, Coleman M, Mark T.  2010.  Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant.. Oncology (Williston Park). 24(3 Suppl 2):14-21.
Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S et al..  2015.  Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. Leuk Lymphoma. 56(12):3320-8.
Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K et al..  2008.  BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood. 111(3):1101-9.
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R et al..  2015.  Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.. J Clin Oncol. 33(33):3921-9.
Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F et al..  2007.  Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.. Leuk Lymphoma. 48(12):2330-7.
Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN et al..  2007.  Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.. Br J Haematol. 138(5):640-3.
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..  2017.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.